ASCO 2022 Conference Coverage


 

Lecture Summary - ASCO 2022 on Overall Survival by IDH2 Mutant Allele (R140 or R172) in Late-Stage Mutant-IDH2 R/R AML Treated With Enasidenib or Conventional Care Regimens in the Phase 3 IDHENTIFY Trial

5 views
July 9, 2022
0 Comments
Login to view comments. Click here to Login
Leukemia